China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its HR20031 in patients with type 2 diabetes. This marks a significant step forward in the development of a novel treatment option for patients with poorly controlled blood glucose levels.
Drug Profile and Mechanism
HR20031 is an in-house developed fixed-dosage compound slow-release preparation. It combines three active ingredients: the sodium-glucose cotransporter 2 (SGLT2) inhibitor henagliflozin, the dipeptidyl peptidase-4 (DPP4) inhibitor retagliptin, and metformin. The drug lowers blood sugar through three distinct mechanisms of action and is administered orally once daily. This treatment method aims to improve patient compliance, especially for those with type 2 diabetes who have not achieved satisfactory blood glucose control with metformin alone. Currently, there is no similar product on the market in China.-Fineline Info & Tech
